Philadelphia, Pennsylvania--(Newsfile Corp. - February 29, 2024) - A securities fraud class action complaint has been filed that alleges that Invivyd, Inc. (NASADAQ: IVVD) f/k/a Adagio Therapeutics (NASDAQ: ADGI), through certain of its officers and directors, failed to disclose that: (i) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim ADG20 was effective against the Omicron variant of COVID-19 were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (ii) defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis; and (iii) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.
Current Invivyd shareholders who have held Invivyd stock (f/k/a/ Adagio Therapeutics) since before November 29, 2021, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.
If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/invivyd-shareholder-investigation/, contact us at jgrabar@grabarlaw.com, or call Joshua Grabar at 267-507-6085.
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/199857
